Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS

NCT03094637 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03094637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03094637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With MDS
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Unknown status
Start date
November 6, 2017
Completion date
November 6, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk myelodysplastic syndrome, ipss risk category intermediate-1, myelodysplastic syndrome